amoxicillin / Generic mfg. - LARVOL DELTA

Performance comparison of O3 and O3/Peroxymonosulfate (PMS) advanced oxidation processes for the antibiotics removal in wastewater treatment. (PubMed, J Hazard Mater) - "For ciprofloxacin-resistant and chloramphenicol-resistant bacteria, both O3 and O3/PMS showed a continuous decrease in concentration with increasing treatment time. For amoxicillin-resistant, tetracycline-resistant, and sulfamethoxazole-resistant bacteria, O3 showed an initial increase followed by a subsequent decrease, while O3/PMS showed a similar trend for tetracycline- and sulfamethoxazole- resistant bacteria, but a continuous decrease for amoxicillin-resistant bacteria...The results indicated that O3/PMS had an advantage over O3 in removing antibiotics, DOM, and controlling ARB. However, prolonged treatment increased ARGs diversity and concentration compared to O3 and significantly enhanced the acute toxicity of antibiotic-containing wastewater."

Journal

Vancomycin Sensitization in Pseudomonas aeruginosa is Contingent on Limited Metabolic Flux. (PubMed, ACS Infect Dis) - "The global antibiotic resistance crisis causes nearly 5 million deaths annually. Our findings show that P. aeruginosa can also be sensitized to other gram-positive-specific antibiotics, such as erythromycin, chloramphenicol, and amoxicillin, with no apparent correlation to the antibiotic's size or mechanism. These findings highlight how different growth conditions affect the susceptibility of P. aeruginosa to clinically relevant antibiotics."

Journal • Infectious Disease

Genomic analysis and pneumococcal population dynamics across PCV implementation in South Korea, 1997-2023. (PubMed, Microb Genom) - "Antimicrobial non-susceptibility was highest for azithromycin (82.7%), followed by tetracycline (76.5%) and co-trimoxazole (70.4%), with higher rates observed in the post-PCV13 period. Notably, amoxicillin (P=0.049) and meropenem (P=0.002) showed significant non-susceptibility in the post-PCV13 period...These findings underscore the importance of genomic surveillance to monitor pneumococcal population dynamics and inform public health strategies. The inclusion of serotype 10A in the recently approved PCV20 offers promise for further reducing the global burden of IPDs, including in South Korea."

Journal • Infectious Disease • Pneumococcal Infections • Pneumonia

Efficacy Comparison of Vonoprazan Combined With Different Antibiotics in Dual Therapy for Helicobacter Pylori Eradication: A Prospective, Randomized Controlled Clinical Trial (clinicaltrials.gov) - P4 | N=400 | Recruiting | Sponsor: Yongquan Shi

New P4 trial • Dyspepsia • Gastric Cancer • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Oncology • Peptic Ulcer • Solid Tumor

Comparative Effectiveness of Empiric Treatment for Helicobacter pylori in a Large, Diverse Population in the United States. (PubMed, Clin Gastroenterol Hepatol) - "In a large, community-based U.S. population, concomitant and bismuth-quadruple therapies had the highest eradication rates for H. pylori for initial treatment without a substantial decline in efficacy over time, while bismuth quadruple was the most successful salvage regimen. History of macrolides or metronidazole use should be reviewed to inform treatment selection. Repeat use of previously prescribed regimens should be avoided."

HEOR • Journal • Infectious Disease

Fourteen-day vonoprazan-amoxicillin dual therapy versus 14-day bismuth-based quadruple therapy for Helicobacter pylori treatment: a randomized clinical trial. (PubMed, Therap Adv Gastroenterol) - P4 | "Participants were randomly assigned (1:1) to receive 14-day VA dual therapy or BQT (lansoprazole, bismuth, amoxicillin, and clarithromycin). Given its reduced antibiotic usage and lower adverse events, it may be a viable first-line alternative for H. pylori in southern China. This trial was registered on the Chinese Clinical Trial Registry with the registration number ChiCTR2200055752."

Clinical • Journal • Infectious Disease

Overcoming antimicrobial resistance in Helicobacter pylori: the roles of collateral sensitivity and biofilm dynamics. (PubMed, J Antimicrob Chemother) - "Biofilm formation plays a critical role in H. pylori AMR, reinforcing the challenge of eradication. CS profiling indicates that resistance acquisition can be exploited therapeutically to enhance antibiotic efficacy. Integrating CS-based treatment strategies with biofilm-disrupting interventions may provide a novel approach of overcoming multi-drug resistance in H. pylori. Further research is required to elucidate the molecular mechanisms underpinning CS and biofilm-mediated resistance to refine treatment strategies."

Journal • Infectious Disease

Assessment of a Stepwise Intervention to Improve Nurse-administered Penicillin Allergy Screening and De-labeling in Pediatric Inpatients. (PubMed, Pediatr Qual Saf) - "Allergy de-labeling demonstrated special cause variation following the dissemination of a standardized amoxicillin challenge order set and then again after a brief period of audit and feedback; however, the increases were not sustained. A nurse-administered screening questionnaire and protocolized follow-up actions can help achieve safe de-labeling at hospitals without a dedicated penicillin allergy service."

Journal • Allergy • Immunology • Infectious Disease • Pediatrics

A non-enzymatic doxycycline absorbance sensor based on manganese-doped zinc sulfide nanoparticles coated with chitosan. (PubMed, PLoS One) - "The need for doxycycline detection is urgent because it is a vital antibiotic extensively utilized to combat bacterial diseases in humans and animals, and it is now at the forefront of the global battle against antibiotic resistance. The sensor also obtains excellent selectivity when testing with other analytes, including glucose, amoxicillin, tetracycline, penicillin, ampicillin, and cephalexin. The capabilities of these ZnS: Mn/Chitosan-based sensors mark a significant advancement in antibiotic monitoring, offering promising applications in clinical settings for patient care and environmental surveillance, thereby playing a critical role in curbing the spread of antibiotic resistance globally."

Journal • Infectious Disease

Surge in macrolide dispensing to Swiss children in a period of increased incidence of Mycoplasma pneumoniae detection: an interrupted time-series analysis. (PubMed, JAC Antimicrob Resist) - "We analysed amoxicillin use as a control outcome...We found a 3-fold increase in macrolide monthly DDD per 1000 children in autumn 2023 in the context of a global increase in M. pneumoniae infections. Monitoring macrolide resistance and promoting appropriate prescription practices are essential."

Journal • Infectious Disease • Pneumonia

Potential short-term shift in oral microbiota of patients with stage III-IV periodontitis and type 2 diabetes treated by non-surgical periodontal therapy. (PubMed, J Dent Sci) - "Seventeen subjects in the test group received scaling and root planing (SRP) and antibiotics (500 mg of amoxicillin [AMX], and 200 mg of metronidazole [MTZ], three times daily for seven days)...AMX + MTZ had more advantages in the decrease of periodontal pathogens. Periodontists should cautiously use the antibiotics to treat such patients."

Journal • Dental Disorders • Diabetes • Hematological Disorders • Metabolic Disorders • Periodontitis • Type 2 Diabetes Mellitus

Vonoprazan Improves Efficacy of Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Multicenter Randomized Controlled Trial. (PubMed, Helicobacter) - "The 14-day P-CAB-BQT therapy containing amoxicillin and furazolidone provided a satisfactory eradication rate and a good safety profile as rescue treatment for H. pylori eradication, regardless of prior choice of antibiotics and the number of treatment attempts. Shortening the treatment course to 10-11 days could prevent the majority of drug-induced fevers."

Clinical • Journal • Infectious Disease

VONOPRAZAN-AMOXICILLIN DUAL THERAPY WITH OR WITHOUT SACCHAROMYCES BOULARDII SUPPLEMENTATION AS A RESCUE REGIMEN FOR HELICOBACTER PYLORI INFECTION: A RANDOMIZED CONTROLLED TRIAL (UEGW 2025) - No abstract available

Clinical • Infectious Disease

LACIDOPHILIN TABLETS SUPPLEMENTATION COMBINED WITH 10-DAY VONOPRAZAN-AMOXICILLIN DUAL THERAPY FOR HELICOBACTER PYLORI ERADICATION: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (UEGW 2025) - No abstract available

Clinical • Infectious Disease

THE EFFECT OF SUPPLEMENTING WITH SACCHAROMYCES BOULARDII ON VONOPRAZAN-AMOXICILLIN DUAL THERAPY FOR NAIVE HELICOBACTER PYLORI INFECTION: A RANDOMIZED CONTROLLED TRIAL (UEGW 2025) - No abstract available

Clinical • Infectious Disease

IMPACT OF PROBIOTICS ON GUT MICROBIOTA AND METABOLOME DURING HIGH-DOSE DUAL THERAPY WITH VONOPRAZAN AND AMOXICILLIN AS HELICOBACTER PYLORI RESCUE THERAPY: A PROSPECTIVE, MULTICENTER, RANDOMIZED CONTROLLED STUDY (UEGW 2025) - No abstract available

Clinical • Gut Microbiota • Infectious Disease

Efficacy of different vonoprazan administration time combined with low-dose amoxicillin dual therapy for helicobacter pylori eradication (IDDF 2025) - "Serological examination showed no significant changes in liver and kidney function before and after Hp eradication treatment in both group A and group B. The compliance of group A and group B by ITT analysis were 95.7% (67/70) and 98.6% (69/70).Conclusions Vonoprazan combined with low-dose amoxicillin dual therapy is a safe and effective first-line regimen for Hp eradication regardless of vonoprazan administration times. Considering convenience, we recommend that vonoprazan and amoxicillin are both administrated after meals."

Clinical • Infectious Disease

Vonoprazan: a transformative alternative to PPIS in the management of acid-related disorders – insights from the vast 2 consensus (BSG 2025) - "For H. pylori eradication, triple therapy with Vonoprazan, amoxicillin, and clarithromycin was strongly endorsed (113.0), surpassing PPI-based regimens...Vonoprazan was recommended as a co-therapy to prevent NSAID-induced ulcers (110.0) and low-dose aspirin-related peptic ulcer bleeding (110.8)...The overall mean response scores were: agree: 87±4 (95% CI 84 to 90), strongly agree: 14±3.4 (95% CI 12 to 16), p<0.0001Conclusion Vonoprazan is a superior alternative to PPIs, demonstrating efficacy across diverse scenarios, including severe reflux esophagitis, H. pylori eradication, and NSAID-induced ulcers. Its innovative profile positions it as a transformative option for broader adoption in acid-related disorder management."

Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Peptic Ulcer

One week vs. two weeks vonoprazan containing triple regimen for eradication of helicobacter pylori: a randomized non-inferiority placebo-controlled trial (IDDF 2025) - "Background This study aimed to evaluate the efficacy of a one-week v/s two-week vonoprazan-based triple regime for the eradication of Helicobacter Pylori.Methods In this double-blind randomized placebo-controlled trial participants were randomized into two groups: A two-week regime group consisting of two weeks of vonoprazan therapy with amoxicillin and levofloxacin, and a One-week regime with one week of vonoprazan with similar antibiotics and a second week of placebo. QOLRAD was improved in both groups; those who achieved eradication vs those in which eradication was not achieved. This suggests improvement in quality of life irrespective of H pylori eradication may be related to acid suppression by vonoprazan."

Clinical • Head-to-Head • Infectious Disease

The effect of supplementing with saccharomyces boulardii on vonoprazan-amoxicillin dual therapy for helicobacter pylori rescue treatment: a randomized controlled trial (IDDF 2025) - "Both groups showed similarly good compliance and safety.Conclusions S.boulardii supplementation in vonoprazan-amoxicillin dual therapy significantly improves the H. pylori eradication rate and reduces adverse events. This regimen is a simplified rescue therapy no matter how many times the patients have failed."

Clinical • Infectious Disease

Outsmarting H. pylori: why local cultures hold the key to effective treatment (BSG 2025) - "Antibiotic regimens were:Amoxicillin, metronidazole, clarithromycin, omeprazoleBismuth subsalicylate, metronidazole, tetracycline, omeprazoleResults 78 patients with treatment-resistant H. pylori underwent gastric biopsy and culture...pylori was isolated in 63 cultures, with 15 finding no growth.Culture sensitivities were as follows:View this table:View inline View popup Abstract P283 Table 1 Culture sensitivities to antibioticsOf note, 41% of cultures were resistant to only one antibiotic, or fully sensitive: 24 cultures were sensitive to four antibiotics (21 resistant to metronidazole, 3 resistant to levofloxacin), while 2 cultures were sensitive to all five tested.Conclusions Our data highlights significant variability in H. pylori antibiotic resistance within a local population, with particularly high metronidazole resistance...Biofilm formation by H. pylori has been found in vivo, and could confer antibiotic resistance despite culture sensitivity. N-acetylcysteine..."

Extranodal Marginal Zone Lymphoma • Gastric Adenocarcinoma • Gastric Cancer • Hematological Malignancies • Infectious Disease • Lymphoma • Marginal Zone Lymphoma • Oncology • Solid Tumor

Comparative effectiveness of ebtt aad ebat regimen for the eradication of helicobacter pylori (IDDF 2025) - "According to the Asia-Pacific recommendations, as well as the Maastricht V consensus and the 2016 Toronto consensus, in countries where the prevalence of H. pylori resistance to clarithromycin and metronidazole exceeds 15%, the recommended first-line treatment is a 4-drug regimen that includes bismuth...However, in Vietnam, there are currently no studies evaluating the effectiveness of a 4-drug regimen that uses tinidazole instead of metronidazole and amoxicillin instead of tetracycline for initiating H. pylori treatment.Methods To determine the eradication rates of two regimens, EBTT (Esomeprazole-Bismuth-Tinidazole-Tetracycline) and EBAT (Esomeprazole-Bismuth-Tinidazole-Amoxicillin), in the treatment of H. pylori.A prospective, randomized controlled study...The most common adverse effects were black stool (25.3%); bitter mouth (11.4%); diarrhea (11.4%); nausea (3.8%); fatigue (2.5%).Conclusions The eradication rate of H.pylori with EBTT regimen was 96.5% and EBAT was..."

HEOR • Fatigue • Gastroenterology • Infectious Disease

SnS2-TiO2 Heterojunction Designed for Reductive Degradation of Contaminants of Emerging Concern. (PubMed, Nanomaterials (Basel)) - "Photocatalytic experiments with amoxicillin (AMX) and perfluorooctanoic acid (PFOA) revealed distinct degradation behaviors: AMX was predominantly degraded via superoxide-mediated reductive pathways, whereas PFOA exhibited limited transformation, likely proceeding via a combination of oxidative and reductive mechanisms. While overall removal efficiencies were moderate, this study highlights the role of band structure engineering and heterojunction design in tailoring photocatalytic behavior. The SnS2-TiO2 system serves as a promising platform for further development of composite materials to address the challenge of CECs in water treatment."

Journal

Amoxicillin Resistance: An In Vivo Study on the Effects of an Approved Formulation on Antibiotic Resistance in Broiler Chickens. (PubMed, Animals (Basel)) - "Worryingly, 20 types of vancomycin resistance genes were detected across all samples. Plasmid-borne ARGs and mobile genetic elements decreased in the ¼× group. Even subtherapeutic antibiotic exposure significantly reshapes the gut microbiota composition and ARG landscape, highlighting the need for refined risk assessments and microbiome-conscious antimicrobial policies in poultry farming."

Journal • Preclinical

A Randomized Trial Comparing Direct Challenges to Penicillin Skin Testing for Outpatient Low-Risk Penicillin Allergy Evaluations in Pregnancy. (PubMed, J Allergy Clin Immunol Pract) - "For evaluation of penicillin allergy in pregnancy, we demonstrate that a DC is as safe as PST in low-risk pregnant patients."

Journal • Allergy • Immunology • Infectious Disease